A Graphene-Based Bioactive Product with a Non-Immunological Impact on Mononuclear Cell Populations from Healthy Volunteers

We previously described GMC, a graphene-based nanomaterial obtained from carbon nanofibers (CNFs), to be biologically compatible and functional for therapeutic purposes. GMC can reduce triglycerides’ content in vitro and in vivo and has other potential bio-functional effects on systemic cells and th...

Full description

Saved in:
Bibliographic Details
Main Authors: María del Prado Lavín-López, Mónica Torres-Torresano, Eva María García-Cuesta, Blanca Soler-Palacios, Mercedes Griera, Martín Martínez-Rovira, José Antonio Martínez-Rovira, Diego Rodríguez-Puyol, Sergio de Frutos
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Nanomaterials
Subjects:
Online Access:https://www.mdpi.com/2079-4991/14/23/1945
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850260576322715648
author María del Prado Lavín-López
Mónica Torres-Torresano
Eva María García-Cuesta
Blanca Soler-Palacios
Mercedes Griera
Martín Martínez-Rovira
José Antonio Martínez-Rovira
Diego Rodríguez-Puyol
Sergio de Frutos
author_facet María del Prado Lavín-López
Mónica Torres-Torresano
Eva María García-Cuesta
Blanca Soler-Palacios
Mercedes Griera
Martín Martínez-Rovira
José Antonio Martínez-Rovira
Diego Rodríguez-Puyol
Sergio de Frutos
author_sort María del Prado Lavín-López
collection DOAJ
description We previously described GMC, a graphene-based nanomaterial obtained from carbon nanofibers (CNFs), to be biologically compatible and functional for therapeutic purposes. GMC can reduce triglycerides’ content in vitro and in vivo and has other potential bio-functional effects on systemic cells and the potential utility to be used in living systems. Here, immunoreactivity was evaluated by adding GMC in suspension at the biologically functional concentrations, ranging from 10 to 60 µg/mL, for one or several days, to cultured lymphocytes (T, B, NK), either in basal or under stimulating conditions, and monocytes that were derived under culture conditions to pro-inflammatory (GM-MØ) or anti-inflammatory (M-MØ) macrophages. All stirpes were obtained from human peripheral mononuclear cells (PBMCs) from anonymized healthy donors. The viability (necrosis, apoptosis) and immunological activity of each progeny was analyzed using either flow cytometry and/or other analytical determinations. A concentration of 10 to 60 µg/mL GMC did not affect lymphocytes’ viability, either in basal or active conditions, during one or more days of treatment. The viability and expression of the inflammatory interleukin IL-1β in the monocyte cell line THP-1 were not affected. Treatments with 10 or 20 µg/mL GMC on GM-MØ or M-MØ during or after their differentiation process promoted phagocytosis, but their viability and the release of the inflammatory marker activin A by GM-MØ were not affected. A concentration of 60 µg/mL GMC slightly increased macrophages’ death and activity in some culture conditions. The present work demonstrates that GMC is safe or has minimal immunological activity when used in suspension at low concentrations for pre-clinical or clinical settings. Its biocompatibility will depend on the dose, formulation or way of administration and opens up the possibility to consider GMC or other CNF-based biomaterials for innovative therapeutic strategies.
format Article
id doaj-art-d2cbcfc107314de89af64a2cfc98bba9
institution OA Journals
issn 2079-4991
language English
publishDate 2024-12-01
publisher MDPI AG
record_format Article
series Nanomaterials
spelling doaj-art-d2cbcfc107314de89af64a2cfc98bba92025-08-20T01:55:37ZengMDPI AGNanomaterials2079-49912024-12-011423194510.3390/nano14231945A Graphene-Based Bioactive Product with a Non-Immunological Impact on Mononuclear Cell Populations from Healthy VolunteersMaría del Prado Lavín-López0Mónica Torres-Torresano1Eva María García-Cuesta2Blanca Soler-Palacios3Mercedes Griera4Martín Martínez-Rovira5José Antonio Martínez-Rovira6Diego Rodríguez-Puyol7Sergio de Frutos8Graphenano S.L., 30510 Yecla, SpainDepartment of Immunology and Oncology, National Center for Biotechnology, Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, SpainDepartment of Immunology and Oncology, National Center for Biotechnology, Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, SpainDepartment of Immunology and Oncology, National Center for Biotechnology, Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, SpainGraphenano S.L., 30510 Yecla, SpainGraphenano S.L., 30510 Yecla, SpainGraphenano S.L., 30510 Yecla, SpainDepartment of Medicine, Universidad de Alcalá, Nephrology Service at Hospital Príncipe de Asturias, Instituto Ramon y Cajal de Investigación Sanitaria, Fundación Renal Iñigo Álvarez de Toledo, 28871 Alcalá de Henares, SpainDepartment of Systems Biology, Universidad de Alcalá, Instituto Ramon y Cajal de Investigación Sanitaria, Fundación Renal Iñigo Álvarez de Toledo, 28871 Alcalá de Henares, SpainWe previously described GMC, a graphene-based nanomaterial obtained from carbon nanofibers (CNFs), to be biologically compatible and functional for therapeutic purposes. GMC can reduce triglycerides’ content in vitro and in vivo and has other potential bio-functional effects on systemic cells and the potential utility to be used in living systems. Here, immunoreactivity was evaluated by adding GMC in suspension at the biologically functional concentrations, ranging from 10 to 60 µg/mL, for one or several days, to cultured lymphocytes (T, B, NK), either in basal or under stimulating conditions, and monocytes that were derived under culture conditions to pro-inflammatory (GM-MØ) or anti-inflammatory (M-MØ) macrophages. All stirpes were obtained from human peripheral mononuclear cells (PBMCs) from anonymized healthy donors. The viability (necrosis, apoptosis) and immunological activity of each progeny was analyzed using either flow cytometry and/or other analytical determinations. A concentration of 10 to 60 µg/mL GMC did not affect lymphocytes’ viability, either in basal or active conditions, during one or more days of treatment. The viability and expression of the inflammatory interleukin IL-1β in the monocyte cell line THP-1 were not affected. Treatments with 10 or 20 µg/mL GMC on GM-MØ or M-MØ during or after their differentiation process promoted phagocytosis, but their viability and the release of the inflammatory marker activin A by GM-MØ were not affected. A concentration of 60 µg/mL GMC slightly increased macrophages’ death and activity in some culture conditions. The present work demonstrates that GMC is safe or has minimal immunological activity when used in suspension at low concentrations for pre-clinical or clinical settings. Its biocompatibility will depend on the dose, formulation or way of administration and opens up the possibility to consider GMC or other CNF-based biomaterials for innovative therapeutic strategies.https://www.mdpi.com/2079-4991/14/23/1945graphenecarbon nanofiberleucocyteslymphocytesnatural killersmonocytes
spellingShingle María del Prado Lavín-López
Mónica Torres-Torresano
Eva María García-Cuesta
Blanca Soler-Palacios
Mercedes Griera
Martín Martínez-Rovira
José Antonio Martínez-Rovira
Diego Rodríguez-Puyol
Sergio de Frutos
A Graphene-Based Bioactive Product with a Non-Immunological Impact on Mononuclear Cell Populations from Healthy Volunteers
Nanomaterials
graphene
carbon nanofiber
leucocytes
lymphocytes
natural killers
monocytes
title A Graphene-Based Bioactive Product with a Non-Immunological Impact on Mononuclear Cell Populations from Healthy Volunteers
title_full A Graphene-Based Bioactive Product with a Non-Immunological Impact on Mononuclear Cell Populations from Healthy Volunteers
title_fullStr A Graphene-Based Bioactive Product with a Non-Immunological Impact on Mononuclear Cell Populations from Healthy Volunteers
title_full_unstemmed A Graphene-Based Bioactive Product with a Non-Immunological Impact on Mononuclear Cell Populations from Healthy Volunteers
title_short A Graphene-Based Bioactive Product with a Non-Immunological Impact on Mononuclear Cell Populations from Healthy Volunteers
title_sort graphene based bioactive product with a non immunological impact on mononuclear cell populations from healthy volunteers
topic graphene
carbon nanofiber
leucocytes
lymphocytes
natural killers
monocytes
url https://www.mdpi.com/2079-4991/14/23/1945
work_keys_str_mv AT mariadelpradolavinlopez agraphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT monicatorrestorresano agraphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT evamariagarciacuesta agraphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT blancasolerpalacios agraphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT mercedesgriera agraphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT martinmartinezrovira agraphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT joseantoniomartinezrovira agraphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT diegorodriguezpuyol agraphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT sergiodefrutos agraphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT mariadelpradolavinlopez graphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT monicatorrestorresano graphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT evamariagarciacuesta graphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT blancasolerpalacios graphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT mercedesgriera graphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT martinmartinezrovira graphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT joseantoniomartinezrovira graphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT diegorodriguezpuyol graphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers
AT sergiodefrutos graphenebasedbioactiveproductwithanonimmunologicalimpactonmononuclearcellpopulationsfromhealthyvolunteers